BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
PPARA
,
nitric oxide metabolic process
,
Lung cancer
,
Heart
,
Acetaminophen
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Ro 48-5033
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
No studies found
Explore Curated Studies Results
Literature
Most Relevant Literature
Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKII-OATP1B1-CYP3A4-UGT1A1-MRP…
Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based …
Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subj…
Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mec…
Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formul…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Persistent Pulmonary Hypertension of the Newborn
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmon…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ